# =============================================================================
# CORE ENTITIES MODULE
# =============================================================================
# File: core/01_entities.yaml
# Lines: ~100
# Maintainer: Business Operations Team
# Purpose: Core business entities (brands, regions, therapeutic areas)
# =============================================================================

brands:
  remibrutinib:
    therapeutic_area: "Immunology"
    indication: "Chronic Spontaneous Urticaria (CSU)"
    abbreviation: "REMI"
    status: "active"
    
  fabhalta:
    therapeutic_area: "Hematology"
    indication: "Paroxysmal Nocturnal Hemoglobinuria (PNH) and rare diseases"
    abbreviation: "FAB"
    status: "active"
    
  kisqali:
    therapeutic_area: "Oncology"
    indication: "HR+/HER2- breast cancer"
    abbreviation: "KIS"
    status: "active"

therapeutic_areas:
  description: "Therapeutic areas covered by E2I platform"
  values:
    - immunology
    - hematology
    - oncology

regions:
  description: "Geographic regions for US operations"
  values:
    - northeast
    - south
    - midwest
    - west
  
  mapping:
    northeast:
      states: ["CT", "MA", "ME", "NH", "NJ", "NY", "PA", "RI", "VT"]
    south:
      states: ["AL", "AR", "DE", "FL", "GA", "KY", "LA", "MD", "MS", "NC", "OK", "SC", "TN", "TX", "VA", "WV"]
    midwest:
      states: ["IA", "IL", "IN", "KS", "MI", "MN", "MO", "ND", "NE", "OH", "SD", "WI"]
    west:
      states: ["AK", "AZ", "CA", "CO", "HI", "ID", "MT", "NM", "NV", "OR", "UT", "WA", "WY"]

data_sources:
  description: "External data providers for E2I platform"
  
  iqvia:
    type: "prescription_data"
    description: "Prescription claims and physician activity"
    
  veeva:
    type: "crm_data"
    description: "Sales force engagement and rep activity"
    
  flatiron:
    type: "ehr_data"
    description: "Electronic health records and clinical outcomes"
    
  optum:
    type: "claims_data"
    description: "Medical and pharmacy claims"

brand_indication_mapping:
  description: "Mapping of brands to their specific indications"
  
  remibrutinib:
    primary_indication: "Chronic Spontaneous Urticaria"
    icd10_codes: ["L50.1", "L50.8", "L50.9"]
    
  fabhalta:
    primary_indication: "Paroxysmal Nocturnal Hemoglobinuria"
    icd10_codes: ["D59.5"]
    secondary_indications: ["Other rare diseases"]
    
  kisqali:
    primary_indication: "HR+/HER2- breast cancer"
    icd10_codes: ["C50.0", "C50.1", "C50.2", "C50.3", "C50.4", "C50.5", "C50.6", "C50.8", "C50.9"]
